-
Product Insights
NewThree Prime Repair Exonuclease 1 – Drugs In Development, 2024
The Three Prime Repair Exonuclease 1 pipeline drugs market research report outlays comprehensive information on the Three Prime Repair Exonuclease 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Solid Tumor, and Unspecified Cancer. It also reviews key players involved in Three Prime Repair Exonuclease 1 targeted therapeutics development with respective active...
-
Product Insights
NewPrime Discoveries Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Prime Discoveries Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Prime Discoveries Inc (Prime Discoveries) develops rapid, novel diagnostics for pathogen infections. Prime Discoveries is headquartered in New York City, New York, the US. GlobalData's Medical Devices company profile report, “Prime Discoveries Inc Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile report provides key information and...
-
Company Insights
NewAmazon Pay – Competitor Profile
Amazon Pay was launched in 2007 as Pay with Amazon, before being rebranded to its current name in 2017. The solution enables users to pay for purchases on third-party partner merchant websites and apps using payment methods saved on the user’s Amazon profile. In the US, Amazon Pay accepts credit and debit cards from major scheme providers including Visa, Mastercard, Discover, American Express, Diners Club, and JCB. In India, users can add funds to their Amazon Pay balance and use...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATP-150 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATP-150 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATP-150 in Pancreatic Ductal Adenocarcinoma Drug Details: ATP-150 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATP-152 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATP-152 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATP-152 in Pancreatic Ductal Adenocarcinoma Drug Details: ATP-152 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INKmune in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INKmune in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INKmune in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target MAGE-A3 For Solid Tumors in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target MAGE-A3 For Solid Tumors in Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus To Target...
-
Sector Analysis
NewUnited States (US) Sports Broadcasting Media (Television and Telecommunications) Market Landscape
The United States Media Landscape Report provides an overview of the television and telecommunications market in relation to sports broadcasting in the United States today, with top-level data and detailed forecasts of key indicators up to 2028. The report analyses the television, SVOD, mobile handset and residential fixed-line broadband sectors, as well as a review of major sports media rights.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target MAGE-A3 For Solid Tumors in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target MAGE-A3 For Solid Tumors in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus...
-
Sector Analysis
NewRwanda Insurance Industry – Key Trends and Opportunities to 2028
GlobalData’s 'Rwanda Insurance Industry: Key Trends and Opportunities to 2028’ report provides in-depth market analysis, information, and insights into the Rwanda insurance industry. The report provides a detailed outlook by product category for the Rwanda insurance industry. It provides values for key performance indicators such as gross written premium, penetration, premium accepted and ceded, profitability ratios, and premium by line of business, during the review period (2019–23) and forecast period (2024–2028). The report also analyzes distribution channels operating in the...